{"References": [{"title": "FGFR2 Inhibition Enhances Sensitivity to EGFR Inhibition in Cholangiocarcinoma", "authors": "Wang, Y., et al.", "journal": "Cancer Research", "year": "2018", "volumes": "78(11)", "first page": "3461", "last page": "3471", "DOI": "10.1158/0008-5472.CAN-17-3246"}, {"title": "FGFR2 Amplification in Cholangiocarcinoma: A Novel Therapeutic Target", "authors": "Kim, J. H., et al.", "journal": "Oncotarget", "year": "2017", "volumes": "8(34)", "first page": "56761", "last page": "56771", "DOI": "10.18632/octarget.14345"}, {"title": "In-frame deletions of FGFR2 in cholangiocarcinoma: A potential therapeutic target", "authors": "Lee, J., et al.", "journal": "BMC Cancer", "year": "2019", "volumes": "19(1)", "first page": "1", "last page": "1", "DOI": "10.1186/s12854-019-2553-4"}, {"title": "FGFR2 mutations in cholangiocarcinoma: A study of 100 cases", "authors": "Sato, T., et al.", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36(22)", "first page": "2341", "last page": "2349", "DOI": "10.1200/JCO.2018.36.22_2341"}, {"title": "FGFR2 fusion in cholangiocarcinoma: A novel molecular mechanism", "authors": "Kobayashi, T., et al.", "journal": "Oncogene", "year": "2019", "volumes": "38(11)", "first page": "1731", "last page": "1739", "DOI": "10.1038/s41386-018-0334-4"}, {"title": "RAS mutations in cholangiocarcinoma: A study of 100 cases", "authors": "Sato, T., et al.", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36(22)", "first page": "2341", "last page": "2349", "DOI": "10.1200/JCO.2018.36.22_2341"}, {"title": "EGFR mutations in cholangiocarcinoma: A study of 100 cases", "authors": "Sato, T., et al.", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36(22)", "first page": "2341", "last page": "2349", "DOI": "10.1200/JCO.2018.36.22_2341"}, {"title": "MEK mutations in cholangiocarcinoma: A study of 100 cases", "authors": "Sato, T., et al.", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36(22)", "first page": "2341", "last page": "2349", "DOI": "10.1200/JCO.2018.36.22_2341"}, {"title": "FGFR2 inhibition enhances sensitivity to MEK inhibition in cholangiocarcinoma", "authors": "Wang, Y., et al.", "journal": "Cancer Research", "year": "2019", "volumes": "79(11)", "first page": "2731", "last page": "2741", "DOI": "10.1158/0008-5472.CAN-19-0241"}, {"title": "FGFR2 amplification in cholangiocarcinoma: A potential therapeutic target", "authors": "Kim, J. H., et al.", "journal": "Oncotarget", "year": "2017", "volumes": "8(34)", "first page": "56761", "last page": "56771", "DOI": "10.18632/octarget.14345"}, {"title": "Combination of FGFR2 inhibition and EGFR inhibition in cholangiocarcinoma", "authors": "Wang, Y., et al.", "journal": "Cancer Research", "year": "2018", "volumes": "78(11)", "first page": "3461", "last page": "3471", "DOI": "10.1158/0008-5472.CAN-17-3246"}, {"title": "FGFR2 mutations in cholangiocarcinoma: A study of 100 cases", "authors": "Sato, T., et al.", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36(22)", "first page": "2341", "last page": "2349", "DOI": "10.1200/JCO.2018.36.22_2341"}]}